EUVIMEDEUVIMED entdecken
Crossref

Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair

Zichen Xu iD, Heng Zhang, Shaohua Gou iD

Inorganic Chemistry · 2026

DOI: 10.1021/acs.inorgchem.6c00964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inorganic Chemistry, 2026. Verfasst von Zichen Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced and Applied Chemical Synthesis, College of Pharmacy, Jinan University, Guangzhou 510632, PR China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, DNA Repair, Poly (ADP-Ribose) Polymerase-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

By applying our pioneering "Targeted Drug Conjugate (TDC)" concept, a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported. In vitro biological assays indicated that the representative compound Ola-604 could target PARP1, exhibit an inhibitory effect on SKOV3 cancer cells, and overcome cisplatin resistance via inducing cell apoptosis, causing cell cycle arrest, enhancing the cellular accumulation of platinum element, promoting the level of DNA platination within the genome, and suppressing DNA damage repair. Notably, compound Ola-604 demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsDNA RepairPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsOrganoplatinum CompoundsHumansFemaleAnimalsMiceApoptosisCell ProliferationDNA DamageDrug Screening Assays, AntitumorCell Line, TumorMice, Nude

Substanzen

Antineoplastic AgentsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPARP1 protein, humanOrganoplatinum Compounds

Autor:innen und Institutionen

  • Institute for Advanced and Applied Chemical Synthesis, College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
  • Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China.

ORCID-Profile: Zichen Xu, Shaohua Gou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, Z., Zhang, H., & Gou, S. (2026). Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.6c00964

Vancouver

Xu Z, Zhang H, Gou S. Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair. Inorganic Chemistry. 2026. doi:10.1021/acs.inorgchem.6c00964

BibTeX
@article{Xu2026,
  author = {Xu, Zichen and Zhang, Heng and Gou, Shaohua},
  title = {Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair},
  journal = {Inorganic Chemistry},
  year = {2026},
  doi = {10.1021/acs.inorgchem.6c00964}
}
Kostenlos starten →